As the top one ERs ranked by their associated interactions in lung adenocarcinoma (LUAD), KEAP1 mutation could affect treatment outcomes of ICB through modulating immune infiltration and immune‐related pathways in lung cancer.31 Here, KEAP1 is linked to lung adenocarcinoma.